NCT04135495View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

October 3, 2022

Study Completion Date

October 3, 2022

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX-02

ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)

DRUG

Ivacaftor

CFTR potentiator

Trial Locations (10)

21287

Johns Hopkins, Baltimore

43205

Nationwide Children's Hospital, Columbus

77030

Baylor College of Medicine, Houston

80206

National Jewish Health, Denver

90806

Long Beach Memorial, Long Beach

94305

Stanford School of Medicine, Palo Alto

02451

Boston Children's Hospital, Boston

T2N 4N1

Foothills Hospital Calgary (University of Calgary), Calgary

M5B-1W8

St. Michael's Hospital, Toronto

H2X0A9

The University of Montreal Health Centre, Montreal

Sponsors
All Listed Sponsors
lead

Eloxx Pharmaceuticals, Inc.

INDUSTRY

NCT04135495 - A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele | Biotech Hunter | Biotech Hunter